{
  "id": "5e48b1ddd14c9f295d000012",
  "type": "yesno",
  "question": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?",
  "ideal_answer": "No. Atalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
    "http://www.ncbi.nlm.nih.gov/pubmed/28861122",
    "http://www.ncbi.nlm.nih.gov/pubmed/26788129"
  ],
  "snippets": [
    {
      "text": "INTERPRETATION: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we summarize the pathophysiological mechanisms involved in the development of SPMS and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of MS, to exert beneficial effects in reducing disease progression unrelated to relapses in SPMS. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788129",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\n\nNatalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Natalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive MS , but it did demonstrate a benefit on a prespecified component of the 9-Hole Peg Test . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28861122",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nNatalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we summarize the pathophysiological mechanisms involved in the development of SPMS and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of MS, to exert beneficial effects in reducing disease progression unrelated to relapses in SPMS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788129",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}